In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BI and Vitae partner on 11beta-HSD1 inhibitors for diabetes

Executive Summary

Boehringer Ingelheim GMBH and small-molecule drug developer Vitae Pharmaceuticals have agreed to identify 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors for diabetes and other metabolic diseases such as obesity and dyslipidemia, and for hypertension. The companies will combine their respective programs and identify candidates to advance toward clinical testing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register